6 recruiting, 5 completed, 3 withdrawn, 2 active not recruiting. 18 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Recruiting 6, Completed 5, Withdrawn 3, Active not recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
Follow Angiosarcoma: new trials by email Literature Review of Angiosarcoma trials Research Report on Angiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma Vusolimogene Oderparepvec (VO), Pembrolizumab - Angiosarcoma, Angiosarcoma, Adult | Phase 2 | Recruiting | Varun Monga, MBBS | 18 | 2026-01-09 | 2026-09-01 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma AGEN2034, AGEN1884 - Angiosarcoma | Phase 2 | Withdrawn | Agenus Inc. | 2021-02-01 | 2022-01-11 | |
| Propranolol in Angiosarcoma Propranolol - Angiosarcoma | Phase 2 | Completed | The Netherlands Cancer Institute | 14 | 2019-12-27 | 2023-11-22 |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Eribulin - Angiosarcoma, Epithelioid Hemangioendothelioma | Phase 2 | Completed | Massachusetts General Hospital | 13 | 2018-01-18 | 2026-08-28 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) PROPRANOLOL - Angiosarcoma | Phase 1 / Phase 2 | Unknown | Assistance Publique Hopitaux De Marseille | 24 | 2016-05-01 | 2016-04-11 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Evaluation of Votrient in Angiosarcoma Pazopanib + Paclitaxel - Angiosarcoma | Phase 2 | Terminated | Heidelberg University | 26 | 2014-07-01 | 2022-03-22 |
| Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Paclitaxel, Bevacizumab - Angiosarcoma | Phase 2 | Completed | Centre Oscar Lambret | 70 | 2010-09-10 | 2026-03-13 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
| Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes gemcitabine, docetaxel, bevacizumab - Sarcoma, Leiomyosarcoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 47 | 2009-04-01 | 2016-01-25 |
Hemangiosarcoma (18) · Sarcoma (9) · Leiomyosarcoma (8) · Liposarcoma (6) · Neurofibrosarcoma (6) · Fibrosarcoma (5) · Histiocytoma, Malignant Fibrous (5) · Sarcoma, Synovial (5) · Dermatofibrosarcoma (4) · Osteosarcoma (3) · Bone Neoplasms (2) · Carcinoma, Adenoid Cystic (2) · Carcinosarcoma (2) · Cholangiocarcinoma (2) · Desmoplastic Small Round Cell Tumor (2)
Neoplasms by Histologic Type (18) · Neoplasms, Connective and Soft Tissue (18) · Neoplasms, Vascular Tissue (18) · Neoplasms (17) · Neoplasms, Connective Tissue (10) · Neoplasms, Fibrous Tissue (10) · Sarcoma (9) · Neoplasms, Muscle Tissue (8) · Neoplasms, Nerve Tissue (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Neurofibroma (6) · Neuromuscular Diseases (6) · Peripheral Nervous System Diseases (6) · Peripheral Nervous System Neoplasms (6)
Doxorubicin (4) · Docetaxel (3) · Gemcitabine (3) · Paclitaxel (3) · Propranolol (3) · pembrolizumab (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Bevacizumab (2) · Ifosfamide (2) · Ipilimumab (2) · Nivolumab (2) · pazopanib (2) · spartalizumab (2) · 4-hydroxy-N-desmethyltamoxifen (1) · ARX788 (1)
Brown University (2) · Agenus Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Centre Oscar Lambret (1) · Fudan University (1) · HRYZ Biotech Co. (1) · Heidelberg University (1) · Instituto do Cancer do Estado de São Paulo (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Niels Junker (1) · QuantumLeap Healthcare Collaborative (1) · St. Jude Children's Research Hospital (1) · The Netherlands Cancer Institute (1)
United States (9) · China (2) · France (2) · Austria (1) · Brazil (1) · Denmark (1) · Germany (1) · Guam (1) · Netherlands (1) · Norway (1) · Sweden (1)
Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Camila MV Moniz, Doctor (1) · Don S Dizon, MD (1) · Galina G Lagos, MD (1) · Gregory Cote, MD, PhD (1) · Jessica Gartrell, MD (1) · Laura Esserman, MD, MBA (1) · Neeltje Steeghs, MD PhD (1) · Niels Junker, MD, PhD (1) · Peter Hohenberger, MD (1) · Sandip P Patel (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 30305054, PMID 31969335, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34529000, PMID 34716198, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38243705, PMID 38358334, PMID 38745646, PMID 39067873, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39613746, PMID 39625569, PMID 39856213, PMID 40402690, PMID 40526879, PMID 40551254, PMID 40588371, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41672597, PMID 41879562
2009 (1), 2015 (1), U10CA180888 (1)